Iberogast® for Healthcare Professionals

References

  1. Allescher HD. Functional dyspepsia – A multicausal disease and its therapy. Phytomedicine 2006; SV 13: 2-11
  2. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV.Gastroenterology 2016; 150: 1262-1279
  3. Ehrlein HJ, Schemann M. Gastrointestinal Motility. http://humanbiology.wzw.tum.de/fileadmin/Bilder/tutorials/tutorial.pdf
  4. El-Serag HB, Talley NJ. Systematic review: health related quality of life in functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 387-393
  5. Germann I et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®). Phytomedicine 2006; 13: SV 45-50
  6. Heinle H, Hagelauer D, Pascht U, Kelber O, Weiser D. Intestinal spasmolytic effects of STW 5 (Iberogast®) and its components. Phytomedicine 2006; 13: SV 75-79
  7. Hohenester B, Rühl A, Kelber O, Schemann M. the herbal preparation STW-5 (lberogast®) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil 2004; 16: 765-773
  8. Iberogast® Product Information Leaflet (PIL) from Germany 2016
  9. Kelber O, Gaedcke F, Steinhoff B, Winterhoff H on behalf of the Working Group “Efficacy and Safety” of Kooperation Phytopharmaka, Bonn (Germany). Ethanol in herbal medicinal products in children. Pharm Ind 2008; 70: 1124-1127
  10. Kroll U, Cordes C. Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 2006; 13: SV 12-19
  11. Layer P, Andresen V, Pehl C, Allescher H. Irritable Bowel Syndrome: German Consensus Guidelines on Definition, Pathophysiology and Management. German Society of Digestive and Metabolic Diseases (DGVS) and German Society of Neurogastroenterology and Motility (DGNM). Z Gastroenterol 2011; 49: 237-293
  12. Liu CY, Müller MH, Glatzle J, Weiser D, Kelber O, Enck P, Grundy D, Kreis ME. The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759-764
  13. Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations. Aliment Pharmacol Ther 2004; 19: 271-279
  14. Melzer J, Rösch W, Reichling J, et al. Metaanalysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20: 1279-1287
  15. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282-1284
  16. Nieber K, Michael S, Grotzinger K, Rauwald JW, Kelber O. Anti-inflammatory effect of STW 5, STW 6 and isolated extracts on the rat small intestine. Z Phytotherapie 2008; 29: S29
  17. Ottillinger B et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65-72
  18. Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, Holtmann G, Feinle-Bisset C. Effects of Iberogast on Proximal Gastric Volume, Antropyloroduodenal Motility and Gastric Emptying in Healthy Men. Am J Gastroenterol 2007; 102: 1276-1283
  19. Quigley EMM. Review article: gastric emptying in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20 (Suppl. 7): 56-60
  20. Rösch W, Vinson B, Sassin I. A randomized clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 2002; 40: 401-408
  21. Schemann M, Michel K, Hohenester B, Ruhl A. Region-specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90-99
  22. Schempp H, Totha A, Weiser D, Elstnera E. Antioxidative Properties of Iberis amara Extracts in Biochemical Model Reactions. Arzneim-Forsch / Drug Res 2003; 53: 568-577
  23. Spiller R, Garsed K. Postinfectious Irritable Bowel Syndrome. Gastroenterology 2009; 136: 1979-1988
  24. Vinson B. Development of Iberogast: Clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert 2009; pp. 167-189
  25. Vinson BR, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with Functional Dyspepsia and Irritable Bowel Syndrome. Gastroenterology 2013; 144: S682 (Mo1881)
  26. Wagner H. Multitarget therapy - The future of treatment for more than just function dyspepsia. Phytomedicine 2006; 13: SV 122-129
  27. Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogast®). Phytomedicine 2006; 13: SV 20-35
  28. Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, Talley NJ. Gastroduodenal Disorders. Gastroenterology 2016; 150: 1380-1392
  29. Lacy BE, Mearin F, Chang L,3 Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology 2016; 150: 1393-1407
  30. Brendler T, Gruenwald J et al. Lemon Balm (Melissa officinalis L.): An evidence-based systematic review by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy 2005; 5: 71-114
  31. Ritter R, Schatton WFH, Gessner B, Willems M. Clinical trial on standardised celandine extract in patients with functional epigastric complaints: results of a placebo-controlled double-blind trial. Complementary Therapies in Medicine 1993; 1: 189-193
  32. Harries N, James KC, Pugh WK. Antifoaming and carminative actions of volatile oils. Journal of Clinical Pharmacy 1978; 2: 171-177
  33. Russo M, Gaynes B, Drossmann D. A national survey of practice patterns of gastroenterologists with comparison to the past two decades. Journal of Clinical Gastroenterology 1999; 29(4), 339-343
  34. Suzuki H, Hibi T. Overlap syndrome of functional dyspepsia and irritable bowel syndrome - are both diseases mutually exclusive. Journal of Neurogastroenterlology and Motility 2011; 17(4), 360-365